(6-Phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methanamine | 1002310-51-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: (6-Phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methanamine
• CAS: 1002310-51-1
• 化学式: C₁₂H₁₁N₅
• 分子量: 225.253
• InChiKey: YPHJBEMWJNBPJH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  69.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  8-Bromo-2-(4-methylpiperazin-1-yl)-6-(trifluoromethyl)quinoxaline 、 (6-Phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methanamine 在 tris-(dibenzylideneacetone)dipalladium(0) 、 caesium carbonate 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 作用下， 以 1,4-二氧六环 为溶剂， 反应 12.0h， 以75%的产率得到3-(4-methylpiperazin-1-yl)-N-[(6-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methyl]-7-(trifluoromethyl)quinoxalin-5-amine
  参考文献：
  名称：

  多取代喹喔啉和吡啶并[ 2,3-d ]嘧啶类化合物：酪氨酸激酶c-Met抑制剂的合成和SAR研究

  摘要：

  通过用喹喔啉和吡啶并[2,3- d ]嘧啶骨架取代我们较早的铅2（zgwatinib）的喹啉支架，设计了两个系列的新类似物。在喹喔啉系列中观察到中等的c-Met抑制活性。在吡啶并[2,3- d ]嘧啶系列中，具有O-键的化合物13a - c无活性，而与N-连接的类似物15a - c保留c-Met抑制能力。在3-硝基苄基类似物15b中观察到最高的活性，其IC 50值为6.5 nM。正在对该化合物进行进一步的结构修饰。

  DOI：

  10.1016/j.bmcl.2012.08.075

文献信息

• Expeditious one-pot synthesis of C3-piperazinyl-substituted quinolines: key precursors to potent c-Met inhibitors
  作者：Yuanxiang Wang、Jing Ai、Gang Liu、Meiyu Geng、Ao Zhang

  DOI：10.1039/c1ob05830d

  日期：——

  An effective one-pot synthesis of quinolines bearing diverse C3-piperazinyl functions was developed by using a modified Friedländer's protocol. The method not only enables the synthesis of our early reported c-Met inhibitor on a large scale, but also provides a way to generate novel multi-substituted quinolines for further structure–activity relationship (SAR) study.

  一种有效的单锅合成具有多样化C3-哌嗪基团的喹啉的方法被开发出来，采用了改进的Friedländer反应。该方法不仅能够大规模合成我们早期报道的c-Met抑制剂，还为生成新型多取代喹啉提供了一种途径，以便进一步进行结构-活性关系（SAR）研究。
• Fused heterocyclic derivatives and methods of use
  申请人：Albrecht Brian K.

  公开号：US20090124612A1

  公开（公告）日：2009-05-14

  Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  所选化合物对于预防和治疗疾病，如HGF介导的疾病具有有效性。本发明包括新颖的化合物、类似物、前药和其药学上可接受的盐、药物组合物和预防和治疗涉及癌症等疾病和其他疾病或病况的方法。该发明还涉及制备这样的化合物的过程，以及在这样的过程中有用的中间体。
• FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE
  申请人：ALBRECHT Brian K.

  公开号：US20120148531A1

  公开（公告）日：2012-06-14

  Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  选定的化合物对于预防和治疗疾病，如HGF介导的疾病，具有有效性。该发明涵盖了新颖的化合物、类似物、前药和其药学上可接受的盐、制药组合物以及用于预防和治疗涉及癌症等疾病和其他疾病或病情的方法。该发明还涉及制备这种化合物的过程以及在这种过程中有用的中间体。
• [1,2,4]TRIAZOLO[4,3-A]PYRIDINE DERIVATIVES USEFUL AS INHIBITORS OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR
  申请人：Amgen, Inc

  公开号：EP3093289A1

  公开（公告）日：2016-11-16

  Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  所选化合物可有效预防和治疗疾病，如 HGF 介导的疾病。本发明包括新型化合物、类似物、原药及其药学上可接受的盐、药物组合物以及用于预防和治疗涉及癌症等疾病和其他弊病或病症的方法。本发明还涉及制造此类化合物的工艺以及在此类工艺中有用的中间体。
• [1,2,4]Triazolo[4,3-a]pyridine derivatives useful as inhibitors of the hepatocyte growth factor receptor
  申请人：Amgen Inc.

  公开号：EP2081931B1

  公开（公告）日：2016-08-31